Biomedical Sciences

Overview

The Programme

Our 120-credit Masters are spread over two years, and the choice of a professional focus will ensure your expertise in one of the following areas:

• PRECLINICAL RESEARCH at the University of Namur – centres your learning on the laboratory phase of research into new disease-causing mechanisms, as well as products and techniques before they are tested on humans. It is based on a solid grounding in fundamental research (current topics in molecular and cellular biology, cell models, elective classes in deverent research fields etc.), biopharmaceutics (pharmacotherapy, health technology assessment, biosynthetic drugs and pharmacovigilance), biotechnology and therapy (clinical and non-clinical experimental approaches, biomedical engineering).

• CLINICAL RESEARCH at the University of Namur – a joint degree with the University of Liège – is based around the research carried out on human beings when products and techniques are sufficiently far-advanced. This Master is offered by UNamur but also relies on the expertise of the University of Liège, which provides all courses related to this professional focus.

• BIOMEDICAL DATA MANAGEMENT at the University of Liège – a joint degree with the University of Namur - offered by ULiège, this master benefits from the renowned expertise in data management of UNamur’s Faculty of Computer Science.

Our 60-credit Master lasts one year and provides a basic grounding in Biomedical Sciences, in particular in the field of biopharmaceuticals.

Your objectives

• To lead scientific projects which aim for greater understanding of the molecular and cellular mechanisms of pathologies and to improve treatment: to analyse raw data, interpret the results and present observations clearly;

• To master every stage of the development of new therapies, in particular biotechnology- or cell-related therapies;

• To develop biomarkers related to different therapies, for example using genetics and pharmacogenomics;

• To lead and monitor preclinical or clinical trials and to be responsible for the administrative management of testing;

• To ensure the production quality of biotechnological and biosimilar products, cell therapies (stem cells), gene therapies, tissue engineering, medical devices (implants, drug delivery devices, etc.) and so on;

• To monitor the quality, safety and efficiency of a drug before it is placed on the market.